C&EN7h
US EPA names 2024 Green Chemistry Challenge Awards recipients
Awardees were recognized for developing renewable lubricant base oils and ethyl acetate, more environmentally-friendly ...
precisionmedicineonline7h
FDA Panel Finds Limited Immunotherapy Benefit in PD-L1-Negative Gastric, Esophageal Cancer
The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.
MedPage Today9h
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...
The Pharma Letter17h
FDA panel votes against broader use of checkpoint blockers
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...
Targeted Oncology1d
FDA ODAC Votes Against Checkpoint Inhibitors in PD–L1-Negative Esophageal Cancer
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...
Targeted Oncology1d
FDA ODAC Finds Limited Benefit for Checkpoint Inhibitors in Low PD-L1 Gastric Cancer
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...
The Pharma Letter1d
Miss for Merck’s favezelimab combo in colorectal cancer
Merck's Phase III KEYFORM-007 trial, testing a combination of favezelimab and Keytruda, failed to meet its primary endpoint ...
Pharmaceutical Technology1d
MHLW approves MSD’s KEYTRUDA for lung and urothelial cancers
The Japanese MHLW has granted approval for MSD’s KEYTRUDA (pembrolizumab) for lung and urothelial cancer indications.
Medpage Today on MSN1d
Med Student Eats 720 Eggs; More Deli Meat Deaths; Hospital CEO in Criminal Contempt
A Harvard medical student who ate 720 eggs in a month-- an estimated 133,200 milligrams of cholesterol -- said his LDL ...
Pharmabiz1d
Merck’s Keytruda gets new approvals in Japan for certain patients with NSCLC and radically unresectable urothelial carcinoma
Rahway, New Jersey Thursday, September 26, 2024, 09:00 Hrs [IST] ...
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
On Thursday, 26 September, the FDA's Oncologic Drugs Advisory Committee will discuss the use of immune checkpoint inhibitors ...
precisionmedicineonline2d
FDA Expert Panel to Consider Limiting Gastric, Esophageal Cancer Immunotherapies to PD-L1 Expressors
The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.